Ultragenyx Pharmaceutical Inc. Annual Share-based Payment Arrangement, Expense in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Ultragenyx Pharmaceutical Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2012 to 2023.
  • Ultragenyx Pharmaceutical Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $39.4M, a 13.6% increase year-over-year.
  • Ultragenyx Pharmaceutical Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $145M, a 10% increase year-over-year.
  • Ultragenyx Pharmaceutical Inc. annual Share-based Payment Arrangement, Expense for 2023 was $135M, a 3.72% increase from 2022.
  • Ultragenyx Pharmaceutical Inc. annual Share-based Payment Arrangement, Expense for 2022 was $130M, a 24.2% increase from 2021.
  • Ultragenyx Pharmaceutical Inc. annual Share-based Payment Arrangement, Expense for 2021 was $105M, a 22.4% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $135M +$4.85M +3.72% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-21
2022 $130M +$25.4M +24.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-21
2021 $105M +$19.2M +22.4% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 $85.7M +$3.74M +4.56% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-17
2019 $82M +$1.89M +2.36% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 $80.1M +$12.1M +17.8% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-12
2017 $68M +$19.7M +40.8% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-14
2016 $48.3M +$23.4M +94.1% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-20
2015 $24.9M +$19.5M +361% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-21
2014 $5.39M +$4.74M +721% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-17
2013 $657K -$234K -26.3% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-26
2012 $891K Jan 1, 2012 Dec 31, 2012 10-K 2015-03-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.